Member Info for alphabravo321

See post title.

I hear the date changed to tomorrow, is this correct?

I think ASCO might be confused with AACR

Google Michael Kelly Narcan

https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022

I have emailed the EMA via their online query form and they responded to say that a decision is yet to be reached on the AMYT application, they said to monitor EMA CHMP minutes and agendas so maybe we wait till next month.

This is an interesting point. From the FDA's perspective, although Filsuvez was not as effective at the 90 day point there was significant efficacy demonstrated at the primary endpoints. Considering the fact that the safety profile was good and there is no other approved therapy, I find it hard to see how they won't approve based on the AMRYT push to have KOLs on EB involved from an early stage. If patient advocacy groups are saying we want this and it is safe, surely that is better than no treatment at all.Then again, what do I know, the FDA approved OxyContin for headaches.

Nice to see Amyt planning something positive

https://capital.com/how-attractive-is-the-healthcare-sector-for-investors-right-now

https://financialpost.com/globe-newswire/amryt-announces-new-patents-for-oleogel-s10

Me too, I have been here a very long time!

So the EMA CHMP meeting commences Monday week, will they give the go/no go before the FDA? I had assumed they would be more inclined to follow the FDA lead so could a delay to CHMP be on the cards?

My shares on Davy Ireland have transferred but Degiro still no progress

Are you thinking what I’m thinking?

They were first on at 1800, very good financial from from CFO

http://www.aim-awards.co.uk/shortlist/

http://wsw.com/webcast/canaccord42/amyr/

Last trade at $14.38 roughly £2.28 a share

https://www.proactiveinvestors.co.uk/companies/news/923743/amryt-pharma-s-joe-wiley-delighted-as-company-begins-trading-on-nasdaq-923743.html

doesn't seem to be in a hurry to show any trades!